749261-96-9

Upstream product

• 19432-69-0 methyl 5-methylthiophene-2-carboxylate 
• 56921-01-8 5-methyl-4-nitro-thiophene-2-carboxylic acid methyl ester 
• 1007389-09-4 methyl 5-[2-(dimethylamino)ethenyl]-4-nitrothiophene-2-carboxylate 
• 36050-35-8 5-methyl-4-nitro-thiophene-2-carboxylic acid 
• 749261-94-7 methyl 5-[(E)-2-(dimethylamino)ethenyl]-4-nitrothiophene-2-carboxylate 

Downstream Products

• 914498-11-6 methyl 6-cyclohex-1-en-1-yl-4H-thieno[3,2-b]pyrrole-2-carboxylate 
• 1007386-84-6 4H-thieno[3,2-b]pyrrole-2-carboxylic acid 

Relevant academic research and scientific papers

A novel approach to 4H-thieno[3,2-b]pyrroles

The condensation of 3-nitro-5-carboxy-2-methylthiophene with acetals of amides proceeds smoothly, and further ammonium formate-Pd/C reduction of nitroenamines thus obtained affords 2-carboxythieno-(5-R)-[3,2-b]pyrroles (R = H, Me) in good yields.

BICYCLIC HETEROCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as modulator of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated disease, disorder, syndrome or condition such as pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases or cancer.

THIENOPYRROLE DERIVATIVES AS ITK INHIBITORS

The present invention is directed to thienopyrrole compounds of formula (I) as Tec kinase inhibitors, in particular ITK (interleukin-2 inducible tyrosine kinase) inhibitors. Also provided herein are processes for preparing compounds described herein, inte

FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE

This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O?X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

Thienopyrrole compound and use thereof as HCV polymerase inhibitor

The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

THIENOPYRROLES AS ANTIVIRAL AGENTS

The present invention relates to tetracyclic thienopyrrole compounds of formula (I), wherein Ar, A, D1, D2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.